Fortitude Family Office’s Janux Therapeutics JANX Stock Holding History

Fortitude Family Office’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.67K	Hold	239	–	–	﹤0.01%	1219
2026 Q1	$3.32K	Buy	239 +32	+15%	+$439	﹤0.01%	1086
2025 Q4	$2.86K	Hold	207	–	–	﹤0.01%	1030
2025 Q3	$5.06K	Sell	207 -16	-7%	-$390	﹤0.01%	808
2025 Q2	$5.15K	Buy	223 +16	+8%	+$422	﹤0.01%	780
2025 Q1	$5.59K	Hold	207	–	–	﹤0.01%	699
2024 Q4	$11.1K	Hold	207	–	–	﹤0.01%	605
2024 Q3	$9.4K	Hold	207	–	–	﹤0.01%	591
2024 Q2	$8.67K	Hold	207	–	–	﹤0.01%	441
2024 Q1	$7.79K	Sell	207 -30	-13%	-$653	0.01%	456
2023 Q4	$2.54K	Buy	+237	New	+$2.05K	﹤0.01%	833

Other funds holding JANX

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Fortitude Family Office's JANX Position: Q2 2026 in Review

Fortitude Family Office held its Janux Therapeutics (JANX) position steady in Q2 2026 at 239 shares worth $3.67K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

Fortitude Family Office first reported a position in JANX in Q4 2023 and has held it in 11 quarters since. The position peaked at $11.1K in Q4 2024. 24 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Fortitude Family Office held 239 shares of Janux Therapeutics worth $3.67K as of Q2 2026.
Fortitude Family Office left its Janux Therapeutics share count unchanged in Q2 2026.
Janux Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1219 holding.
Fortitude Family Office first reported a position in Janux Therapeutics in Q4 2023 and has held it in 11 quarters since.
Fortitude Family Office's Janux Therapeutics position peaked at $11.1K in Q4 2024.
24 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.